Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors

NCT03728361 is registered in ClinicalTrials.gov with Dwight Owen as lead sponsor.

NCT NCT03728361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03728361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors
Lead sponsor
Dwight Owen
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2018
Completion date
December 2, 2025
Enrollment
55 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

grade i neuroendocrine carcinoma, grade ii neuroendocrine carcinoma, grade iii neuroendocrine carcinoma, large cell neuroendocrine carcinoma, lung cancer stage iv, metastatic neuroendocrine carcinoma, neuroendocrine carcinoma, neuroendocrine tumors, recurrent small cell lung carcinoma, refractory small cell lung carcinoma, small cell lung cancer metastatic, small-cell lung cancer